Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Product liability bill

This article was originally published in The Tan Sheet

Executive Summary

In a Nov. 5 letter to senators and members of the House Commerce Subcommittee, NDMA urged support for product liability legislation (S 687) cosponsored by Sens. Jay Rockefeller (D- W.Va.), Slade Gorton (R-Wash.) and others. Characterizing the bill as a "fair" and "responsible" measure, NDMA said that S 687 meets the need for a stable climate in which our members can produce new, safe and effective" OTCs at competitive prices." The bill cleared the Senate Commerce Committee by a 16-4 vote at a Nov. 9 markup and will be referred to the Judiciary Committee and then to the Senate floor. Supporters of S 687 expect consideration by the full Senate in early 1994. As in previous years, the bill contains a provision to protect from punitive damages manufacturers of products considered safe and effective by FDA. No action has been taken on House companion measures HR 1910 and HR 1954.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS082175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel